The interplay between drug resistance and fitness in malaria parasites
Open Access
- 31 July 2013
- journal article
- review article
- Published by Wiley in Molecular Microbiology
- Vol. 89 (6) , 1025-1038
Abstract
Summary: Controlling the spread of antimalarial drug resistance, especially resistance of Plasmodium falciparum to artemisinin‐based combination therapies, is a high priority. Available data indicate that, as with other microorganisms, the spread of drug‐resistant malaria parasites is limited by fitness costs that frequently accompany resistance. Resistance‐mediating polymorphisms in malaria parasites have been identified in putative drug transporters and in target enzymes. The impacts of these polymorphisms on parasite fitness have been characterized in vitro and in animal models. Additional insights have come from analyses of samples from clinical studies, both evaluating parasites under different selective pressures and determining the clinical consequences of infection with different parasites. With some exceptions, resistance‐mediating polymorphisms lead to malaria parasites that, compared with wild type, grow less well in culture and in animals, and are replaced by wild type when drug pressure diminishes in the clinical setting. In some cases, the fitness costs of resistance may be offset by compensatory mutations that increase virulence or changes that enhance malaria transmission. However, not enough is known about effects of resistance mediators on parasite fitness. A better appreciation of the costs of fitness‐mediating mutations will facilitate the development of optimal guidelines for the treatment and prevention of malaria.Keywords
This publication has 124 references indexed in Scilit:
- Na+ Regulation in the Malaria Parasite Plasmodium falciparum Involves the Cation ATPase PfATP4 and Is a Target of the Spiroindolone AntimalarialsCell Host & Microbe, 2013
- Global malaria mortality between 1980 and 2010: a systematic analysisThe Lancet, 2012
- Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trialThe Lancet, 2010
- Ranking of elimination feasibility between malaria-endemic countriesThe Lancet, 2010
- Shrinking the malaria map: progress and prospectsThe Lancet, 2010
- Probing the multifactorial basis of Plasmodium falciparum quinine resistance: Evidence for a strain-specific contribution of the sodium-proton exchanger PfNHEMolecular and Biochemical Parasitology, 2009
- Apicoplast translation, transcription and genome replication: targets for antimalarial antibioticsTrends in Parasitology, 2008
- Advances in understanding the genetic basis of antimalarial drug resistanceCurrent Opinion in Microbiology, 2007
- Combination Therapy for Uncomplicated Falciparum Malaria in Ugandan ChildrenJAMA, 2007
- Transporters involved in resistance to antimalarial drugsTrends in Pharmacological Sciences, 2006